Search all trials

Find therapies in clinical trials near you – page 5

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Triple negative breast cancer

Recruiting

InvestigationalNo placebo

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Contact Research Centre

Biliary neoplasm

Recruiting

Registered drugNo placebo

Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Binimetinib

Contact Research Centre

Breast cancer metastatic

Recruiting

Registered drugNo placebo

Study of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Etoposide

Contact Research Centre

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Recruiting

Registered drugNo placebo

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

Squamous cell carcinoma of head and neck

Recruiting

Registered drugNo placebo

Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Recruiting

Registered drugNo placebo

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Anastrozole

Contact Research Centre

HER2 positive breast cancer

Recruiting

Registered drugNo placebo

Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Pertuzumab

Contact Research Centre

Adenocarcinoma pancreas

Recruiting

InvestigationalNo placebo

Study on 68Ga-FAPI-46 for Imaging in Patients with Non-Metastatic Pancreatic Cancer

InvestigationalNo placebo

France

Participants:18–64 years · 65+ years
Substances:(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-Cyano-4,4-Difluoropyrrolidin-1-Yl)-2-Oxoethylcarbamoyl)-Quinolin-6-Yl)(Methyl)Amino)-Propyl)Piperazin-1-Yl)-2-Oxoethyl)-68Ga-[1,4,7,10]-Tetraazacyclododecane-1,4,7-Triyl)Triacetate

Contact Research Centre

Non-small cell lung cancer stage IV

Recruiting

Registered drugNo placebo

Study on Maintenance Treatment with Pembrolizumab and Pemetrexed for Stage IV Non-Small Cell Lung Cancer Patients After Initial Chemotherapy and Immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Carboplatin

Contact Research Centre

Acute lymphocytic leukaemia+1

Recruiting

Registered drugNo placebo

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Blinatumomab

Contact Research Centre

Endometrial cancer

Not yet recruiting

Registered drugNo placebo

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:GSK5733584

Contact Research Centre

Plasma cell myeloma

Not yet recruiting

Registered drugNo placebo

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Find therapies in clinical trials near you – page 5

133 trials match your criteria

Triple negative breast cancer

Study on Early Detection of Triple-Negative Breast Cancer Relapse Using 68Ga-FAPI-46 for Patients at High Risk

Biliary neoplasm

Study on Maintenance Therapy with Cisplatin, Durvalumab, and Trastuzumab for Patients with Advanced Biliary Cancer

Breast cancer metastatic

Study of Tucatinib, Etoposide, and Trastuzumab for Patients with Metastatic HER2+ Breast Cancer After Progression or Capecitabine Toxicity

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Study of Camizestrant for Patients with ER+/HER2- Early Breast Cancer After 2 Years of Standard Endocrine Therapy

Squamous cell carcinoma of head and neck

Study on the Safety and Effectiveness of VB10.16 and Pembrolizumab for Patients with HPV16-Positive Head and Neck Cancer

Hormone receptor positive HER2 negative breast cancer

Study on Early Detection and Treatment of ER Positive HER2 Negative Breast Cancer Using Palbociclib, Fulvestrant, and Drug Combination for Patients with Molecular Relapse

HER2 positive breast cancer

Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

Adenocarcinoma pancreas

Study on 68Ga-FAPI-46 for Imaging in Patients with Non-Metastatic Pancreatic Cancer

Non-small cell lung cancer stage IV

Study on Maintenance Treatment with Pembrolizumab and Pemetrexed for Stage IV Non-Small Cell Lung Cancer Patients After Initial Chemotherapy and Immunotherapy

Acute lymphocytic leukaemia+1

Study on Blinatumomab, Ponatinib, and Isatuximab for Adults Aged 18-65 with Newly Diagnosed Acute Lymphoblastic Leukemia or T-Cell Lymphoblastic Lymphoma

Endometrial cancer

Study of GSK5733584 versus paclitaxel or doxorubicin in patients with advanced or recurrent endometrial cancer after platinum‑based chemotherapy and immunotherapy

Plasma cell myeloma

Ramantamig (JNJ-79635322) with drug combination versus standard therapy in newly diagnosed multiple myeloma patients not eligible for stem cell transplant

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.